THU0526 Efficacy and Safety of Febuxostat in 73 Gouty Patients with Stage 4/5 Chronic Kidney Disease...
THU0526 Efficacy and Safety of Febuxostat in 73 Gouty Patients with Stage 4/5 Chronic Kidney Disease: Result from A Retrospective 9 Multicenter Study
About this item
Full title
Author / Creator
Juge, P.-A. , Truchetet, M.-E. , Pillebout, E. , Ottaviani, S. , Vigneau, C. , Loustau, C. , Cornec, D. , Pascart, T. , Snanoudj, R. , Bailly, F. , Schaeverbeke, T. , Saraux, A. , Dieudé, P. , Flipo, R.-M. , Richette, P. , Lioté, F. , Bardin, T. , Chales, G. and Ea, H.-K.
Publisher
Kidlington: Elsevier Limited
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: Elsevier Limited
More information
Scope and Contents
Contents
BackgroundAlthough allopurinol reminds the first urate lowering therapy (ULT), its limited dosage in gouty patients with stage 4 or 5 chronic kidney disease (CKD 4/5) prevents to achieve serum uric acid (sUA) level target (<60 mg/l). Febuxostat is a nonpurine xanthine oxidase inhibitor with predominant hepatic metabolism and can be used without dos...
Alternative Titles
Full title
THU0526 Efficacy and Safety of Febuxostat in 73 Gouty Patients with Stage 4/5 Chronic Kidney Disease: Result from A Retrospective 9 Multicenter Study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1901841956
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1901841956
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2016-eular.4817
